ioMicroglia™ – Consistent iPSC-Derived Microglia, Ready in 10 Days!

bit.bio is an award-winning human synthetic biology company based in Cambridge, UK. Our cell identity coding platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency. Having access to human cells has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease and form the basis for a new generation of cell and tissue therapies. It will enable us to realise our vision: biomedical innovation and a new generation of cures through precision reprogrammed human cells. The cell identity coding platform consists of three core parts: our discovery platform which identifies the precise code that defines cell fate; our precision cellular reprogramming technology - opti-ox - that deterministically reprograms stem cells into any cell type; and our world leading expertise in stem cell reprogramming, manufacturing and clinical translation. Using our platform, we have already launched multiple wild type and disease model cells under our ioCells™ brand for research and drug discovery. The platform also means we can offer custom partnership capabilities. And we are currently building our own, in-house cell therapy pipeline using our platform.